PDGFRB and renal cell carcinoma: Sorafenib is a multikinase inhibitor and has potent effects on c-Raf, b-Raf, VEGFR-2, and PDGFR, and it is postulated that the effect of sorafenib on RCC is closely associated with its effect on VEGF receptor [16].